Search for a command to run...
Promoter shareholding in Astec Lifesciences increased by 4.12% YoY, indicating confidence from insiders, while both Institutions and Public shareholding decreased, contrasting sector averages where no changes occurred.
The decline in Institution (-0.04%) and Public (-2.04%) shareholding suggests a lack of interest from smart money and retail investors, reinforcing the stock's status as a laggard in a stable sector environment.
Comparatively, the sector's best performing stocks showed significant institutional buying (12.88%), highlighting Astec Lifesciences' poor relative performance amidst broader sector strength.
| Category | Trend | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
1Promoter Holdings | 66.75% | 66.75% | 66.75% | 66.75% | 66.75% | 70.87% | 70.87% | 72.42% | |
2Public Holdings | 22.23% | 24.12% | 28.84% | 28.21% | 27.42% | 24.54% | 24.85% | 23.57% | |
3Foreign Investors | 1.28% | 1.25% | 1.03% | 0.53% | 1.2% | 0.25% | 0.02% | - | |
4Domestic Investors | 9.74% | 7.88% | 3.38% | 4.51% | 4.63% | 4.34% | 4.26% | 4.01% |